Background Although the increased risk of cardiovascular disease in patients with SLE is well-documented, effective tools for ...

Objectives Despite significant therapeutic progress in systemic lupus erythematosus (SLE), adopting a treat-to-target strategy remains challenging. While disease activity monitoring is well ...

Objective Lupus nephritis (LN) is a major cause of morbidity and mortality, affecting up to 60% of patients with systemic lupus erythematosus (SLE). The perspectives of patients with SLE have been ...

Objectives To evaluate the Systemic Lupus International Collaborating Clinics-Frailty Index (SLICC-FI) as a predictor of hospitalisations in patients with SLE from a Latin American cohort. Methods ...

Objective We previously reported that lupus anticoagulant (LAC) is the main predictor of poor pregnancy outcome in antiphospholipid antibody (aPL)-positive patients. We sought to confirm this finding ...

Objective Lupus erythematosus (LE) is a complicated disease with highly heterogeneous clinical manifestations. Previous studies have rarely included all subgroups of patients with lupus and have ...

Objective Simple measures of type I interferon (IFN) activity constitute highly attractive biomarkers in systemic lupus erythematosus (SLE). We explore galectin-3-binding protein (G3BP) as a novel ...

Nailfold capillaroscopy is a non-invasive imaging technique for morphological assessment of capillaries in the nailfold area and represents a key method for differentiation of primary and secondary ...

Objective Treatment response in lupus nephritis (LN) is defined based on proteinuria, yet protocol kidney biopsy studies have shown that patients with lupus can have active nephritis in the absence of ...

Background Previous reports indicate that treating patients with lupus (SLE) at or close to the time of diagnosis successfully without using any, or minimal, corticosteroids by using B-cell depletion ...

Background Glucose is a primary substrate for cellular respiration. Glucose utilisation increases in highly metabolic cells including activated, proliferating T cells and B cells as well as cancers.

Objective SLE, primary Sjögren’s syndrome (pSS) and systemic sclerosis (SSc) are heterogeneous autoimmune diseases with a dysregulated type I interferon (IFN) system. The diseases often show ...